Medpace Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDP research report →
Range $515 – $692
Price Chart
About the company
Medpace Holdings, Inc. , founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia.
- CEO
- August James Troendle
- IPO
- 2016
- Employees
- 6,500
- HQ
- Cincinnati, OH, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a long-term uptrend, trading above both the 50-day and 200-day moving averages. It is still well below the 52-week high after a strong run, so the setup looks like a consolidation within a larger bullish cycle rather than a broken trend.
Street sentiment is cautious-to-neutral, with a Hold consensus and a 606.38 target above the last close. The recent pattern is mixed: several firms lifted targets sharply in late July, but rating changes still clustered around Hold and Neutral rather than fresh bullish upgrades.
The company has a strong beat record, going 7-for-7 on the last seven reported quarters. Next quarter is expected to show EPS of 4.45, and the key watch is whether revenue and margin momentum can keep supporting the next-year EPS estimate of 19.3101.
Recent insider activity leans clearly negative, with 10 sales and no open-market buys. The largest moves came from the CEO and other directors, while the M-code entries are routine award-related activity and not the main signal; the discretionary selling is the part shareholders should watch.
Profitability remains strong, led by a 72.3% gross margin and a 20.76% operating margin. Growth is still healthy, with revenue up 17.2% year over year and earnings up 37.1%, while the balance sheet stays net cash positive at $246.6 million.
Medpace stands out on margin quality versus most life-sciences services peers, with high gross and operating profitability supporting premium valuation. At 34.66 times earnings, the stock still trades at a full multiple, so execution has to stay clean to justify it.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.28B
- P/E
- 33.53
- Fwd P/E
- 33.13
- PEG
- 1.30
- P/S
- 5.85
- P/B
- 38.05
- EV/EBITDA
- 26.39
- Div Yield
- 0.00%
- Gross Margin
- 28.76%
- Op Margin
- 20.97%
- Net Margin
- 17.67%
- ROE
- 110.15%
- ROIC
- 77.00%
Latest fiscal year · YoY change
- Revenue
- $2.53B+20.0%
- Gross Profit
- $760.62M+15.9%
- Op Income
- $534.93M
- Net Income
- $451.12M+11.6%
- EPS
- $15.64+19.8%
- OCF Growth
- +17.1%
- FCF Growth
- +19.2%
- 52W High
- $677.90
- 52W Low
- $373.00
- 50D MA
- $576.37
- 200D MA
- $520.73
- Beta
- 1.15
- RSI (14)
- 46
- Avg Volume
- 298.16K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medpace posted strong Q2 2026 growth, record net bookings, and raised full-year guidance, while management said the business environment and oncology demand improved as cancellations eased.· July 23, 2026
- Revenue grew 17.2% to $707.3 million; EBITDA rose 17.6% to $153.4 million and EPS increased to $4.25 from $3.10.
- Net new business awards were $795.7 million, up 28.2% year over year, for a 1.13x net book-to-bill.
- Ending backlog was about $3 billion, up 4.9%, with roughly $1.96 billion expected to convert to revenue in the next 12 months.
- Management said cancellations were down sharply from Q1 and that oncology made up over half of bookings and award notifications.
- Full-year 2026 guidance was raised across revenue, EBITDA, net income, and EPS.
- results":"Revenue was $707.3 million in Q2 2026, up 17.2% year over year. EBITDA was $153.4 million, up 17.6%, with EBITDA margin at 21.7% versus 21.6% last year. Net income was $121.4 million, up 34.5% from $90.3 million, and diluted EPS was $4.25 versus $3.10. For the first six months, revenue was $1.41 billion, EBITDA was $302.8 million, and net income was $245.2 million. Net new business awards entering backlog were $795.7 million, up 28.2%, with a 1.13x net book-to-bill; ending backlog was approximately $3 billion, up 4.9%, and about $1.96 billion is expected to convert to revenue over the next 12 months. Cash from operating activities was $162 million, cash at quarter-end was $502.7 million, and the company repurchased about 706 thousand shares for $294.7 million. Full-year 2026 revenue is now expected at $2.805 billion to $2.885 billion, EBITDA at $618 million to $642 million, net income at $494 million to $514 million, and EPS at $17.25 to $17.95. Guidance assumes a 19% to 19.5% tax rate, $21.1 million of interest income, no additional share repurchases, and FX rates as of June 30, 2026.
- ceo":"August Troendle said the business environment was strong in Q2, cancellations were well behaved, and the quarter delivered a record in net bookings. He said RFPs were up sequentially and year over year, and that the company is making good progress positioning the business for 2027. In Q&A he said oncology has come back strongly, that oncology was over half of bookings and award notifications, and that the mix is shifting back toward historical patterns as cardiometabolic work cools off.","cfo":"Kevin Brady highlighted the core financial performance: revenue of $707.3 million, EBITDA of $153.4 million, net income of $121.4 million, and diluted EPS of $4.25. He said margin held at 21.7% in the quarter, while year-to-date EBITDA margin was flat at 21.4% because higher reimbursable costs were offset mainly by lower employee-related costs. He also pointed to $162 million of operating cash flow, negative 59.6 days sales outstanding, $502.7 million of cash, and $527 million remaining on the share repurchase authorization. On guidance, he noted full-year revenue, EBITDA, net income, and EPS ranges were all raised and that the model assumes 41% to 42% of revenue for direct service costs in Q3 and Q4, with some further decline in reimbursable costs expected in the back half.","qanda":"Analysts focused on whether metabolic work and larger customers were driving the strong bookings and whether backlog conversion rates would normalize. Management said the top 5 customer growth was driven by metabolic work, but emphasized that oncology now dominates bookings and award notifications, while the higher backlog burn rate was not mainly a metabolic effect; instead, they cited policy gating on interim decision points, changes in the average age of projects, and the mix of programs entering backlog. Analysts also pressed on cancellations, with management saying Q2 cancellations fell to a very good range and helped net bookings, though they remain hard to predict. Questions on funding, China, and phase mix drew a response that the funding environment has improved broadly, Phase 1 has increased relative to Phase 2, Phase 3 has been stable, and management does not see a major shift of work to China." ,"bull":"The call showed strong demand momentum: record net bookings, a 1.13x book-to-bill, growing backlog, and RFPs that were up meaningfully both sequentially and year over year. Management sounded more constructive on oncology, funding availability, and the second half, while also saying cancellations improved materially from the prior quarter. The raised full-year guidance and ongoing share repurchases reinforce that management sees the current environment as supportive." ,"bear":"Management repeatedly warned that cancellations are unpredictable and can swing results quarter to quarter, so the improved Q2 level may not be durable. The company also said the high backlog conversion rate should moderate over time as the mix of programs and average project age normalizes, which could temper growth rates. In addition, the recent strength has been helped by a mix shift away from cardiometabolic work toward oncology, and management does not expect the current mix to persist indefinitely."}】
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.6%
- Shares Outstanding
- 27.91M
- Float Shares
- 22.50M
of shares held by institutions
742 13F filers
Buy/sell ratio 0.24. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MEDP, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| David J. TaylorHouse · OH02 | Buy | May 14, 26 | Filing → |
| David J. TaylorHouse · OH02 | Buy | Feb 25, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Jan 14, 26 | Filing → |
| David J. TaylorHouse · OH02 | Sell | Jan 15, 26 | Filing → |
| David J. TaylorHouse · OH02 | Buy | Jan 28, 26 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Oct 8, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Aug 3, 25 | Filing → |
| David J. TaylorHouse · OH02 | Sell | Jul 22, 25 | Filing → |
| Gilbert Ray CisnerosHouse · CA31 | Sell | Jul 24, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 21, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Jan 12, 25 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jul 25, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jun 20, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jan 23, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 2.50M | ▲ 27.81K |
| Vanguard Group Inc | 2.26M | ▼ 21.12K |
| Price T Rowe Associates Inc | 2.07M | ▲ 1.78M |
| Aqr Capital Management LLC | 1.28M | ▼ 74.90K |
| Vanguard Portfolio Management LLC | 1.13M | ▲ 11.67K |
| Vanguard Capital Management LLC | 1.03M | ▲ 15.75K |
| State Street Corp | 710.89K | ▲ 28.67K |
| Geode Capital Management, LLC | 710.47K | ▼ 34.64K |
| Wasatch Advisors LP | 636.60K | ▼ 137.34K |
| Invesco Ltd. | 579.24K | ▲ 1.67K |
| Baillie Gifford & Co | 473.21K | ▼ 29.98K |
| Arrowstreet Capital, Limited Partnership | 429.01K | ▲ 33.24K |
Held by 644 ETFs
Biggest fund positions in MEDP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 27, 26 | Troendle August J. | sell | 650 |
| Aug 26, 26 | Kraft Robert O. | other | 3,858 |
| Aug 26, 26 | Kraft Robert O. | sell | 3,858 |
| Aug 26, 26 | Kraft Robert O. | other | 3,858 |
| Aug 25, 26 | Troendle August J. | sell | 673 |
| Aug 26, 26 | Troendle August J. | sell | 4,000 |
| Aug 21, 26 | Troendle August J. | sell | 13,995 |
| Aug 24, 26 | Troendle August J. | sell | 1,983 |
| Aug 20, 26 | Brady Kevin M. | other | 3,400 |
| Aug 20, 26 | Brady Kevin M. | sell | 3,400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MEDP coverage
Recent articles, reports, and earnings notes.
Medpace Holdings (MEDP): Growth Quality vs. Booking Risk
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Clinical Research and Pharma Services Stocks That Reward Quality: 3 Picks
Three clinical research and pharma services stocks ranked by investment quality, weighing scale, execution, profitability, growth, and valuation.
Medpace Holdings, Inc. (MEDP) falls 14.5% after hours
Medpace Holdings, Inc. (MEDP) falls sharply in after-hours trading after a strong post-earnings run. The move looks driven more by profit-taking and valuation pressure than by a new company-specific setback, even as the CRO’s backlog, bookings, and raised guidance remain solid.
Want a deeper read on MEDP?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Medpace (MEDP) is a Top Growth Stock for the Long-Term
zacks.com · Sep 1
American Capital Management Inc. Invests $111.33 Million in Medpace Holdings, Inc. $MEDP
defenseworld.net · Aug 27
Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
investors.com · Aug 26
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
zacks.com · Aug 26
What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock
fool.com · Aug 26
Bank of New York Mellon Corp Takes Position in Medpace Holdings, Inc. $MEDP
defenseworld.net · Aug 26
B. Metzler seel. Sohn & Co. AG Invests $4.74 Million in Medpace Holdings, Inc. $MEDP
defenseworld.net · Aug 22
Allworth Financial LP Makes New Investment in Medpace Holdings, Inc. $MEDP
defenseworld.net · Aug 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed September 5, 2026 · Live quote · Not investment advice